Skip to main content
Premium Trial:

Request an Annual Quote

Bionas, Nexcelom Bioscience

German biotech firm Bionas this week launched the Bionas 2500 analyzing system, a device for in vitro profiling of cellular metabolic activity.
The 2500 measures multiple metabolic parameters, such as acidification, oxygen consumption, and cell adhesion, simultaneously to provide predictive safety pharmacology studies during preclinical drug discovery. The instrument uses a label-free technique based on electronic sensor chips that replace traditional cell culture well plate bottom surfaces.

Nexcelom Bioscience has launched the Cellometer Model Auto T4 Cell Counter, the company said this week.
The Auto T4 automates cell counting using a patent-pending plastic disposable counting chamber. Samples are pipetted into the chamber, and placed into the Auto T4, which connects to a computer. Imaging software measures cell concentration and viability, and cells within a heterogeneous sample can be measured, the company said. The instrument has a footprint of 3.5 inches by 4 inches to “optimize lab space,” and the disposable chamber requires as little as 20 mL of sample, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.